Instructions for PANTOGAM (HOPANTENIC ACID)
English product name
PANTOGAM active
Release form
caps. 300 mg: 30 or 60 pcs
Description
Capsules are solid gelatine, size №0, white color; The contents of the capsules are white or white powder with a yellowish colour.
1 cap.
D,L-gopantenic acid* 300 mg
* racopantene acid.
Auxiliary substances: cellulose microcrystalline - 20.97 mg, magnesium stearate - 1.53 mg.
Composition of hard gelatine capsules: titanium dioxide - 2%, gelatin - up to 100%.
10 pcs - box-type contour (3) packages - cardboard packs.
10 pcs - packages of box contour (6) - cardboard packs.
15 pcs - packages of box contour (2) - cardboard packs.
15 pcs - box-type contour (4) packages - cardboard packs.
ATC codes
N06BX Other psychostimulants and nootropic drugs PANTOGAM
Clinical-pharmacological groups / Group affiliation
Nootropic preparation with anticonvulsive effect
Active substance
D,L-gopantenic acid
Pharmacotherapy group
Nootropic agent
Storage Conditions
The drug PANTOGAM should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years. Do not apply after the expiry date indicated on the package.
Pharmacological effect:
The action of the preparation PANTOGAM asset is due to the presence in its structure of gamma-aminobutyric acid (GABA), which directly affects the GABA-receptor-channel complex. The PANTOGAM asset is a racemic mixture of equal quantities of the R-form of gopantene acid and its S-isomer. The presence of the isomer improves the drug's transport and interaction with the GABA receptor.
PANTOGAM actives have a more pronounced nootropic and anticonvulsive effect than first-generation gopantenic acid preparations.
PANTOGAM Active increases the resistance of the brain to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines moderate sedative action with a mild stimulative effect. It has an anti-asthenic and mild anti-anxiety effect. Reduces motor arousal, regulates behavior. Activates mental activity and performance.
Causes inhibition of pathologically elevated bubble reflex and intruder tone.
Testimony:
cognitive impairment in organic brain lesions (including the effects of neuroinfections and brain injuries) and neurotic disorders;
cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels;
Extrapyramidal hyperkinesis (myoclonus-epilepsy, Gentington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.), as well as for the treatment of extrapyramidal syndrome caused by neuroleptics;
Epilepsy combined with anticonvulsant drugs PANTOGAM;
psycho-emotional overload, reduction of mental and physical efficiency, to improve concentration and memorization;
neurogenic urinary disorders (pollakiuria, imperative calls, imperative urinary incontinence, enuresis);
Schizophrenia in complex therapy.
Method of use, course and dosage^
The preparation is taken internally, 15-20 minutes after eating, preferably in the morning and afternoon hours.
The recommended dose is 1-3 caps. (0.3-0.9 g) 2-3 times/day
Maximum daily dose 8 caps. (2.4).
The course of treatment is 1-4 months, sometimes up to 6-12 months. A second course of treatment is possible after 3-6 months.
Overdose:
Increased symptoms of side effects.
Treatment: Active charcoal, gastric flushing, symptomatic therapy.
Drug interaction:
PANTOGAM Asset prolongs the action of barbiturates, enhances the effects of anticonvulsive agents, prevents side effects of phenobarbital, carbamazepine, neuroleptics.
The effect of the drug PANTOGAM Asset is enhanced when combined with glycine, ethidronic acid.
PANTOGAM activ potentiates the action of local anesthetics (procaine).
Use in pregnancy and breastfeeding
The use of the preparation during pregnancy and during breastfeeding is contraindicated.
Side Effect:
The adverse reactions shown below are listed according to organ and system damage and frequency of occurrence. The frequency is defined as follows: very often (≥1/10), often (≥1/100 and <1/10), infrequently (≥1/1000 and <1/100), rarely (≥1/10,000 and <1/1000), very rarely (<1/10,000, including isolated cases).
From the immune system: Rarely - allergic reactions (rhinitis, conjunctivitis, skin rashes).
Mental disorders: Rarely sleep disorders; Very rarely - drowsiness.
From the nervous system: rarely a headache; Very rarely - dizziness, noise in the head.
On the digestive side: Rarely - nausea, pain in the epigastria.
In the event of an immune system disorder, the drug PANTOGAM should be discontinued. In other cases, the dose of the drug is reduced.
Contraindications for use:
acute severe kidney disease;
the patient's age is under 18 years old (there are no clinical studies on the use of the drug PANTOGAM at this age);
increased sensitivity.
Special Instructions
In long-term conditions, it is not recommended to prescribe the drug PANTOGAM simultaneously with other nootropic and CNS stimulating agents.
Application for kidney disorders
It is contraindicated in severe acute kidney disease.
Terms of Sale
The drug PANTOGAM is prescription.
Use in children
The use of the preparation in the age of up to 18 years is contraindicated.
Nosology (ICD codes)
F07
Personality and behavioural disorders caused by disease, damage or brain dysfunction
F20
Schizophrenia
F21
Schizotypic disorder
F22
Chronic delusional disorder
F23
Acute and transient mental disorders
F25
Schizoaffective disorder
F29
Inorganic psychosis unspecified
F43
Response to severe stress and adaptation disorders
F48.8
Other Refined Neurotic Disorders
F98.0
Enuresis of inorganic nature
G09
Effects of inflammatory diseases of the central nervous system
G10
Guentington Chorea
G20
Parkinson's disease
G21
Secondary parkinsonism
G25.3
Myoclonus
G25.8
Other refined extrapyramidal and motor disorders
G40
Epilepsy
I67.2
Cerebral atherosclerosis
I69
Effects of cerebrovascular disease
N31
Neuromuscular bladder dysfunction not classified elsewhere
T90
Effects of head injuries
Y49.3
Antipsychotic and neuroleptic preparations of phenothiazine series
Y49.4
Neuroleptics of butyrophenone and thioxanthene
Y49.5
Other antipsychotic and neuroleptic drugs
Z73.0
Overwork
Z73.3
Stress conditions not classified in other headings (physical and mental stress)
